Gerresheimer: Bormioli Pharma boosts revenues and earnings
– Revenues +11.6%, Adjusted EBITDA +13.1%
– Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3%
– Q1 significantly influenced by revenue shift in syringe business
– Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22%
Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, recorded a jump in revenues and earnings due to the first-time cons